Opus Genetics, Inc. Net Income Loss

• Opus Genetics, Inc. showed an increase of +13.8% in Net Income Loss from 2024 to 2025.
• This data is from Opus Genetics, Inc.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
• XBRL data for this metric is available from 2003 to 2025 (23 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 23 years of available data (2003 to 2025), Opus Genetics, Inc.'s Net Income Loss has declined by 1,687.0%.
• Historical annual values: Fiscal year 2025: -$49.59 million | Fiscal year 2024: -$57.53 million | Fiscal year 2023: -$9.99 million | Fiscal year 2022: $17.89 million | Fiscal year 2021: -$56.69 million | Fiscal year 2020: -$24.62 million | Fiscal year 2019: -$6.17 million | Fiscal year 2018: -$14.37 million | Fiscal year 2017: -$25.29 million | Fiscal year 2016: -$9.31 million | Fiscal year 2015: -$14.38 million | Fiscal year 2014: -$18.52 million | Fiscal year 2013: -$9.50 million | Fiscal year 2012: -$6.23 million | Fiscal year 2011: -$11.34 million | Fiscal year 2010: -$14.02 million | Fiscal year 2009: -$2.90 million | Fiscal year 2008: -$3.68 million | Fiscal year 2007: -$4.44 million | Fiscal year 2006: -$6.49 million | Fiscal year 2005: -$6.35 million | Fiscal year 2004: -$3.27 million | Fiscal year 2003: -$2.78 million.
• Data sourced from SEC EDGAR public filings as of June 21, 2026.

Last verified: June 21, 2026